Allena Pharmaceuticals: Results Of Operations And Financial Condition

The following excerpt is from the company's SEC filing.
On August 10, 2021, Allena Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2021 and provided a business update. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
The information under this Item 2.02 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Ac t of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
Description
Press release of Allena Pharmaceuticals, Inc. (concerning financial results) dated August 10, 2021, furnished hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 10, 2021
/s/ Richard Katz
Richard D. Katz, M.D.
Chief Financial Officer

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Allena Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Statement of acquisition of beneficial ownership by individuals - Jan. 25, 2022
Allena Pharmaceuticals Provides Clinical And Corporate Update ALLN-346, - Jan. 4, 2022

Auto Refresh

Feedback